Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | CETP | P11597 | 3/20 | 0.40 |
| ▸ | LAP3 | P28838 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15578371 | 0.82 | TSHR (0.50) | NPC1MAPTTSHRALDH1A1RAB9A | |
| SCHEMBL6107327 | 0.80 | EPHX2 (0.46) | SMN1; SMN2CETPHTT | |
| SCHEMBL758293 | 0.80 | TSHR (0.47) | MAPTTSHRALDH1A1RAB9ALMNA | |
| SCHEMBL476827 | 0.79 | TSHR (0.61) | NPC1MAPTTSHRALDH1A1RAB9A | |
| SCHEMBL7147100 | 0.78 | NPC1 (0.57) | NPC1MAPTTSHRALDH1A1RAB9A | |
| SCHEMBL244446 | 0.78 | ALOX15 (0.52) | NPC1TSHRALDH1A1RAB9ALMNA | |
| SCHEMBL187684 | 0.78 | ALOX5 (0.51) | NPC1ALDH1A1RAB9ALMNAPOLB | |
| SCHEMBL4465319 | 0.78 | ALDH1A1 (0.56) | MAPTTSHRALDH1A1RAB9ALMNA | |
| SCHEMBL11379564 | 0.77 | KMT2A (0.40) | NPC1TSHRALDH1A1RAB9APOLB | |
| SCHEMBL5517752 | 0.76 | NPC1 (0.55) | NPC1MAPTTSHRALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2025-01-23 | — | — | US | disclosed |
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2024-08-13 | — | — | US | disclosed |
| EP-4098654-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2022-12-07 | — | — | EP | disclosed |
| CN-114533729-A | Glucosylceramide synthase inhibitors | 建新公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20220073508-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2022-03-10 | — | — | US | disclosed |
| EP-2895484-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORP (US) | 2022-02-23 | — | — | EP | disclosed |
| CN-108864076-B | Glucosylceramide synthase inhibitors | 建新公司 | 2022-02-11 | — | — | CN | disclosed |
| EP-0276124-B1 | PROSTAGLANDIN DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | Sankyo Company Limited (JP) | 1992-05-20 | — | — | EP | disclosed |
| US-4981872-A | ANTIULCER | SANKYO COMPANY LIMITED (JP) | 1991-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GBA1, GBA2, GALC | NPC1 95/4885MAPT 3852/4885TSHR 2547/4885 |
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | NPC1 100/4885MAPT 4277/4885TSHR 2412/4885 |
| US-20220073508-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | NPC1 100/4885MAPT 4277/4885TSHR 2412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.